glp-1 drugs and thyroid cancer Increased screening may lead to higher risk after initiation GLP-1 Thyroid Cancer Human Data:

February 25, 2023

For example, in the context of vascular anti-inflammatory response pertaining to atherosclerosis, GLP-1RA liraglutide was found to inhibit human plasminogen activator inhibitor type-1 secondary to tumor necrosis factor alpha (TNF-alpha) signaling [45]

Clinical evidence: key trials and outcomes The kidney-protective potential of SGLT2 inhibitors was first identified in cardiovascular outcome trials, including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus PatientsRemoving Excess Glucose (EMPA-REG OUTCOME) [36], Canagliflozin Cardiovascular Assessment Study (CANVAS) [37], and Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 (DECLARETIMI 58) [38]

This approach is more precise than relying on the report odds ratio, particularly in situations with limited cases [30]

Piccoli GF, Mesquita LA, Stein C, Aziz M, Zoldan M, Degobi NAH, et al